Nils Lonberg

This inventor holds 68 USPTO granted patents and 34 published patent applications, plus 1 CIPO patent and 17 EPO patents, primarily in Cancer Immunotherapy (CPC class C07K). Top assignees: Bristol-Myers Squibb Compnay, Genpharm International, Inc., Medarex Inc.. Active years: 1996-2026.

USPTO Granted Patents = 68 (Patent Applications = 34)

% Patents Active = 82.4

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 17 (Patent Applications = 23)

Average Co-Inventor Count = 3.6

ph-index = 25

Forward Citations = 12,676(Granted Patents)

Forward Citations (Not Self Cited) = 12,344(Dec 10, 2025)

Inventors with similar research interests:

Location History:

San Francisco, CA (US) (1996 - 1999)
Redwood City, CA (US) (1997 - 2012)
Woodside, CA (US) (2001 - 2024)

Company Filing History:

25 out of 3,736

Bristol-Myers Squibb Compnay

patents

17 out of 28

Genpharm International, Inc.

E. R. Squibb Sons, Inc.

patents

5. 5 out of 272

Kyowa Hakko Kirin Co., Limited

Five Prime Therapeutics, Inc.

patents

9. 2 out of 556

University of Cincinnati

patents

10. 1 out of 42

Kirin Brewery Company, Limited

patents

11. 2 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

Anti-LAG-3

GITR

Cancer Diagnostics

Tumor Treatment

Immunosuppressive B Cells

Transgenic Rodents

Chimeric Antibodies

CD73

Human CTLA-4

Compositions

Optimization

68 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12540194 - ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIES (2026-02-03),

2. 12509527 - ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIES (2025-12-30),

3. 12435136 - Antibodies binding to ILT4 (2025-10-07),

4. 12173081 - CD19/CD38 multispecific antibodies (2024-12-24),

5. 12049503 - Treatment of LAG-3 positive tumors (2024-07-30),

6. 11807686 - Treatment of LAG-3 positive tumors (2023-11-07),

7. 11802162 - Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof (2023-10-31),

8. 11723975 - Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody (2023-08-15),

9. 11408889 - Anti-GITR antibodies for cancer diagnostics (2022-08-09),

10. 11401328 - Antibodies binding to ILT4 (2022-08-02),

11. 11384363 - HCO32 and HCO27 and related examples (2022-07-12),

12. 11352440 - Antibodies against CD73 and uses thereof (2022-06-07),

13. 11345752 - Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2022-05-31),

14. 11299551 - Composite binding molecules targeting immunosuppressive B cells (2022-04-12),

15. 11274152 - Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors (2022-03-15),

Title: The Innovative Journey of Nils Lonberg

Introduction: Nils Lonberg, a pioneering inventor based in Woodside, CA (US), has made significant contributions to the field of biotechnology through his groundbreaking innovations.

Latest Patents: Nils Lonberg holds several patents in the biotechnology sector, focusing on novel methods for drug development and targeted therapies.

Career Highlights: With a distinguished career spanning over two decades, Nils Lonberg has worked with leading research institutions and biopharmaceutical companies to advance the frontiers of biotechnology.

Collaborations: Throughout his career, Nils Lonberg has collaborated with top scientists, researchers, and industry experts to bring cutting-edge inventions to life, revolutionizing the field of biotechnology.

Conclusion: Nils Lonberg's relentless pursuit of innovation and his commitment to pushing the boundaries of biotechnology make him a true visionary in the world of inventors.